Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 13/20 | 0.47 |
| ▸ | JAK3 | P52333 | 12/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 3/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048677 | 0.87 | HTR2A (0.60) | HTR2AHTR2CBTKJAK3SYK | |
| SCHEMBL13079878 | 0.84 | IRAK4 (0.53) | HTR2AHTR2CBTKJAK3SYK | |
| SCHEMBL13048682 | 0.80 | HTR2A (0.57) | HTR2AHTR2CBTKJAK3SYK | |
| SCHEMBL1937577 | 0.80 | SYK (0.50) | SYK | |
| SCHEMBL13079395 | 0.78 | HTR2A (0.63) | HTR2AHTR2CBTKJAK3SYK | |
| SCHEMBL1937791 | 0.78 | CTSC (0.53) | JAK3SYK | |
| SCHEMBL13048651 | 0.77 | ULK1 (0.54) | HTR2AHTR2CBTKJAK3SYK | |
| SCHEMBL13079396 | 0.77 | MERTK (0.65) | HTR2AHTR2CBTKJAK3SYK | |
| SCHEMBL1937543 | 0.76 | SYK (0.50) | SYK | |
| SCHEMBL13048674 | 0.76 | CDK2 (0.60) | HTR2AHTR2CBTKJAK3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298557-A1 | PYRAZOLOPYRIMIDINE COMPOUND | SYK, LCK, FYN | HTR2A 4430/4885HTR2C 4181/4885BTK 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.